A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Stopped early · Phase 1

Conditions studied: Advanced Non-Central Nervous System (CNS) Malignancies

In brief

The purpose of this Phase 1 of the study is to evaluate the effect of food on the pharmacokinetics (PK) of oprozomib, the drug-drug interaction of oprozomib with midazolam, and the safety and tolerability of oprozomib in patients with advanced malignancies

Key facts

Study ID

NCT02244112

Run by

Amgen

People needed

43

Starts

2014-08-01

Expected to finish

2019-07-10

Last updated by the study team

2021-02-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Colorado Anschutz Medical Campus — Aurora, Colorado, United States
• Winship Cancer Institute — Atlanta, Georgia, United States
• Henry Ford Hospital — Detroit, Michigan, United States
• Mary Crowley Cancer Research Centers - Medical City — Dallas, Texas, United States
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas, United States
• Huntsman Cancer Institute — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.